Transversus Abdominus Plane Block in Living Donor Hepatectomy
NCT ID: NCT02708459
Last Updated: 2016-08-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
90 participants
INTERVENTIONAL
2016-03-31
2016-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Transversus Abdominis Plane Block for Postoperative Analgesia in Living Donor Hepatectomy
NCT02645903
Techniques for Perioperative Analgesia for Live Liver Donors; A Pilot Study
NCT03393988
Intraperitoneal Tramadol Versus Dexmedetomedine for Analgesia After Abdominal Laparoscopic Cancer Surgeries
NCT04813016
Paravertebral Morphine Versus Dexmedetomidine on Acute and Chronic Postmastectomy Pain
NCT02935933
Dexamethasone Added in Ultrasound-guided Transversus Abdominis Plain Block for Postoperative Analgesia
NCT02783144
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Control group where postoperative analgesia will be maintained by Morphine intravenous boluses (2 mg) if Visual analogue scale (VAS) scale more than 4.
Intravenous morphine
Boluses of intravenous morphine (2 mg) will be given to patients if Visual analogue scale (VAS) more than 3
Bupevecaine group
Postoperative analgesia will be maintained by 20 ml Bupevecaine (0.25%) boluses in surgically inserted TAP catheter each 8 hours for 48 hours with rescue analgesia intravenous morphine (2mg) if VAS more than 4
surgically inserted Transversus abdominus plane catheter
at end of surgery, a surgeon will insert catheter in Transversus abdominus plane (TAP) between internal oblique muscle and Transversus abdominus muscle
Intravenous morphine
Boluses of intravenous morphine (2 mg) will be given to patients if Visual analogue scale (VAS) more than 3
Bupevecaine
Dex group
catheter will surgically inserted in Transversus abdominus plane (TAP) plane before wound closure Postoperative analgesia will be maintained by Dexmedetomedine 0.4 mg/kg plus Bupevecaine 0.25 20 ml boluses each 8 hours for 48 hours in surgically inserted TAP catheter with rescue analgesia intravenous morphine (2mg) if VAS more 4
surgically inserted Transversus abdominus plane catheter
at end of surgery, a surgeon will insert catheter in Transversus abdominus plane (TAP) between internal oblique muscle and Transversus abdominus muscle
Intravenous morphine
Boluses of intravenous morphine (2 mg) will be given to patients if Visual analogue scale (VAS) more than 3
Bupevecaine
Dexmedetomedine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
surgically inserted Transversus abdominus plane catheter
at end of surgery, a surgeon will insert catheter in Transversus abdominus plane (TAP) between internal oblique muscle and Transversus abdominus muscle
Intravenous morphine
Boluses of intravenous morphine (2 mg) will be given to patients if Visual analogue scale (VAS) more than 3
Bupevecaine
Dexmedetomedine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AlRefaey Kandeel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AlRefaey Kandeel
Dr
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mansoura university
Al Mansurah, Dakahlia Governorate, Egypt
Mansoura university
Al Mansurah, Dkahleya, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Abuelella TAP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.